El Lilly Acquires Centessa for $7.8 B to Boost Neuroscience & Orexin Therapy
Discover how Eli Lilly’s $7.8 B acquisition of Centessa adds orexin‑targeted narcolepsy drugs, boosting its neuroscience portfolio and market impact.
2 minutes to read
CENTESSA PHARMACEUTICALS